ChristosVaklavasMD

PubMed

• 2 citations
  Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
  Maeve A Hennessy, Jeffrey P Leal, Chiung-Yu Huang, Lilja B Solnes, Rita Denbow, Vandana G Abramson, Lisa A Carey, Minetta C Liu, Mothaffar Rimawi, Jennifer Specht, Ann...> ;Journal of Nuclear Medicine. 2023 Nov 1
• 5 citations
  Prospective Pilot Study ofF-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas.
  Matthew F Covington, John M Hoffman, Kathryn A Morton, Brandon Buckway, Kenneth M Boucher, Regina E Rosenthal, Jane M Porretta, Kirstyn E Brownson, Cindy B Matsen, Chr...> ;AJR. American Journal of Roentgenology. 2023 Aug 1
• 1 citations
  A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.
  Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy S Yang, William E Grizzle, And...> ;Breast Cancer Research and Treatment. 2023 Apr 1
• 1 citations
  A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
  John Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, Joanne Jeter, Christos Vaklavas, Umang Swami, Douglas Grossmann, Alyssa Erickson-Wayman, Heloisa P...> ;Frontiers in Immunology. 2023 Jan 1
• 100 citations
  A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
  Katrin P Guillen, Maihi Fujita, Andrew J Butterfield, Sandra D Scherer, Matthew H Bailey, Zhengtao Chu, Yoko S DeRose, Ling Zhao, Emilio Cortes-Sanchez, Chieh-Hsiang Y...> ;Nature Cancer. 2022 Feb 1
• 3 citations
  Automated lesion detection of breast cancer in [F] FDG PET/CT using a novel AI-Based workflow.
  Jeffrey P Leal, Steven P Rowe, Vered Stearns, Roisin M Connolly, Christos Vaklavas, Minetta C Liu, Anna Maria Storniolo, Richard L Wahl, Martin G Pomper, Lilja B Solnes> ;Frontiers in Oncology. 2022 Jan 1
• 2 citations
  The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors.
  Adriana M. Coletta, Mary C. Playdon, Kelly Glazer Baron, Mei Wei, Kristen C. Kelley, Christos Vaklavas, Anna C. Beck, Saundra S. Buys, Jonathan Chipman, Cornelia M. Ul...> ;Plos One. 2021 Oct 12
• Erratum: "Toward improved models of human cancer" [APL Bioeng. 5, 010901 (2021)].
  Bryan E. Welm, Christos Vaklavas, Alana L. Welm> ;APL Bioengineering. 2021 Jun 1
• 20 citations
  Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
  Roisin M. Connolly, Jeffrey P. Leal, Lilja B. Solnes, Chiung-Yu Huang, Ashley Carpenter, Katy Gaffney, Vandana G Abramson, Lisa A. Carey, Minetta C. Liu, Mothaffar F. ...> ;Journal of Clinical Oncology. 2021 May 17
• 24 citations
  An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
  Erica Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla ...> ;Breast Cancer Research. 2021 Mar 4
• 8 citations
  Toward improved models of human cancer.
  Bryan E. Welm, Christos Vaklavas, Alana L. Welm> ;APL Bioengineering. 2021 Jan 4
• 76 citations
  Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
  Young Kwang Chae, Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell, James A. Zwiebel, S. Percy Ivy, Robert Gray, Shuli Li, Lisa...> ;Journal of Clinical Oncology. 2020 May 28
• 8 citations
  TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormon...
  Christos Vaklavas, Brian S. Roberts, Katherine E. Varley, Nan Lin, Minetta C. Liu, Hope S. Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A. Carey, Mans...> ;Breast Cancer Research. 2020 Feb 18
• 5 citations
  Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer.
  Christos Vaklavas, Scott W. Blume, William E. Grizzle> ;Translational Oncology. 2020 Feb 1
• 30 citations
  TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
  Roisin M. Connolly, Jeffrey P. Leal, Lilja Solnes, Chiung Yu Huang, Ashley Carpenter, Katy Gaffney, Vandana G. Abramson, Lisa A. Carey, Minetta C. Liu, Mothaffar F. Ri...> ;Journal of Clinical Oncology. 2019 Feb 5
• 3 citations
  Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition.
  Christos Vaklavas, Kurt R. Zinn, Sharon Samuel, Zheng Meng, William E. Grizzle, Hyoungsoo Choi, Scott W. Blume> ;Oncology Reports. 2018 Jun 1
• 47 citations
  Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.
  Christos Vaklavas, Scott W. Blume, William E. Grizzle> ;Frontiers in Oncology. 2017 Jul 26
• 224 citations
  Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.
  Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, Christos Vaklavas, Nisha Mohindra, Aparna Kalyan, Maria Matsangou, Ricardo Costa, Benedito A. Carneiro, Victor...> ;Oncotarget. 2017 Feb 28
• 11 citations
  IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells
  Christos Vaklavas, William E. Grizzle, Hyoungsoo Choi, Zheng Meng, Kurt R. Zinn, Kedar Shrestha, Scott W. Blume> ;Tumour Biology. 2016 Jul 26
• 93 citations
  Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.
  Andres Forero, Yufeng Li, Dongquan Chen, William E. Grizzle, Katherine L. Updike, Natalie D. Merz, Erinn Downs-Kelly, Todd C. Burwell, Christos Vaklavas, Donald J. Buc...> ;Cancer Immunology Research. 2016 May 1
• 20 citations
  Small molecule inhibitors of IRES-mediated translation
  Christos Vaklavas, Zheng Meng, Hyoungsoo Choi, William E. Grizzle, Kurt R. Zinn, Scott W. Blume> ;Cancer Biology & Therapy. 2015 Jul 15
• 47 citations
  TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-...
  Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nan Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna Maria Storniolo, ...> ;Clinical Cancer Research. 2015 Jun 15
• 66 citations
  Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
  Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William J. Irvin, Nan Lin, Mine...> ;Clinical Cancer Research. 2015 Jun 15
• 14 citations
  Management of Metastatic Breast Cancer With Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE)
  Christos Vaklavas, Andres Forero> ;Biodrugs. 2014 Feb 5
• 9 citations
  Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience.
  Apostolia Maria Tsimberidou, Christos Vaklavas, Siqing Fu, Sijin Wen, Jo Ann Lim, David S. Hong, Jennifer J. Wheler, Aung Naing, Cynthia Uehara, Michael J. Wallace, Ra...> ;Hepato-Gastroenterology. 2013 Oct 1
• Join now to see all